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of β-amyloid plaques
Steffen Burgold1,2, Severin Filser1,2, Mario M Dorostkar1,2, Boris Schmidt4 and Jochen Herms1,2,3*Abstract
A major neuropathological hallmark of Alzheimer’s disease is the deposition of amyloid plaques in the brains of
affected individuals. Amyloid plaques mainly consist of fibrillar β-amyloid, which is a cleavage product of the
amyloid precursor protein. The amyloid-cascade-hypothesis postulates Aβ accumulation as the central event in
initiating a toxic cascade leading to Alzheimer’s disease pathology and, ultimately, loss of cognitive function. We
studied the kinetics of β-amyloid deposition in Tg2576 mice, which overexpress human amyloid precursor protein
with the Swedish mutation. Utilizing long-term two-photon imaging we were able to observe the entire kinetics of
plaque growth in vivo. Essentially, we observed that plaque growth follows a sigmoid-shaped curve comprising a
cubic growth phase, followed by saturation. In contrast, plaque density kinetics exhibited an asymptotic progression.
Taking into account the fact that a critical concentration of Aβ is required to seed new plaques, we can propose
the following kinetic model of β-amyloid deposition in vivo. In the early cubic phase, plaque growth is not limited
by Aβ concentration and plaque density increases very fast. During the transition phase, plaque density stabilizes
whereas plaque volume increases strongly reflecting a robust growth of the plaques. In the late asymptotic phase,
Aβ peptide production becomes rate-limiting for plaque growth. In conclusion, the present study offers a direct link
between in vitro and in vivo studies facilitating the translation of Aβ-lowering strategies from laboratory models to
patients.
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Alzheimer’s disease (AD) is the most common form of de-
mentia and is characterized by the accumulation of amyl-
oid plaques as one major neuropathological hallmark [1].
Amyloid plaques consist mainly of Aβ peptide (Aβ) that is
produced by sequential cleavage of amyloid precursor pro-
tein (APP) by β-secretase and γ-secretase [2]. The amyloid-
cascade-hypothesis postulates that Aβ accumulation is the
central event in the etiology of AD, initiating a toxic cas-
cade that culminates in widespread neurodegeneration
[3-6]. Indeed, recent biomarker studies in humans have
shown that changes in Aβ metabolism and Aβ accumula-
tion initiate about 20 years before the onset of clinical
symptoms [7-10].* Correspondence: Jochen.Herms@med.uni-muenchen.de
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unless otherwise stated.Cloning of the amyloid precursor protein pioneered the
investigation of Aβ aggregation in vitro [11]. Monomers of
Aβ were shown to form higher order aggregates in a time
and concentration dependent manner [12]. The process of
in vitro Aβ aggregation, as well as Aβ accumulation in
humans, with time follows a sigmoidal curve shape
[7,13,14].
In recent years several studies investigated the kinetics
of Aβ aggregation into amyloid plaques in AD mouse
models [15]. Collectively, these studies revealed that newly
formed plaques were initially very small and enlarged
slowly over long periods of time during the early stages of
amyloid pathology [16-20], while late-stage amyloid path-
ology lacked further plaque formation [17,19,21] and
growth [16,17,20,22].
In the present study we aimed at extending this basic
knowledge of in vivo plaque growth kinetics by investi-
gating the close relationship between plaque density and
plaque growth. Furthermore, we were able to monitor
the complete plaque growth kinetics over an observationl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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stage amyloid pathology. In this manner, we found that




Heterozygous Tg2576 [9] mice (B6;SJL-Tg(APPSWE)
2576Kha from Taconic, Cologne, Germany) were kindly
provided by neuroanatomy group of Abbott (Ludwigshafen,
Germany). Tg2576 mice express a human APP with the
Swedish mutation (K670M/N671L) under a hamster prion
protein promoter. Heterozygous APPPS1 mice coexpress a
human APP with the Swedish mutation and a mutated PS1
(L166P) under the neuron-specific Thy1-promoter [23].
Mice were of both sexes (four females in the young cohort
and one male/three females in the old cohort) and group-
housed under pathogen-free conditions until surgery, after
which they were single-housed. All procedures were per-
formed in accordance with an animal protocol approved by
the University of Munich and the Government of Upper
Bavaria [Az. 55.2-1.54-2531-110-06].
Cranial window surgery
A cranial window was implanted over the right cortical
hemisphere as previously reported [24-27]. In short, the
mice were anesthetized with an intraperitoneal injection
of ketamine/xylazine (0.13/0.01 mg/g body weight; WDT/
Bayer Health Care, Garbsen/Leverkusen, Germany). Add-
itionally, dexamethasone (0.02 ml at 4 mg/ml; Sigma) was
intraperitoneally administered immediately before surgery
[28]. A circular piece of the skull (about 5 mm in diameter)
over the right hemisphere (centered over the parietal bone,
approx. 5.5 mm caudal from the bregma and 5.5 mm lateral
from midline) was removed using a dental drill (Schick-
Technikmaster C1; Pluradent; Offenbach, Germany). The
craniotomy was closed immediately with a round coverslip
(5 mm in diameter), held with dental acrylic. A small metal
bar, containing a hole for a screw, was glued next to the
coverslip to allow repositioning of the mouse during subse-
quent imaging sessions. After surgery, mice received sub-
cutaneous analgesic treatment with carprophen (7.5 mg/kg
body weight; Rimadyl; Pfizer, New York, USA) and anti-
biotic treatment with cefotaxim (0.25 mg/g body weight;
Pharmore, Ibbenbüren, Germany).
Long-term two-photon in vivo imaging
Imaging started 3 to 4 weeks after the cranial window
preparation to allow the animals to recover from surgery.
For amyloid staining methoxy-X04 [29] was intraperitone-
ally injected 24 h before imaging. Initially, we administered
a loading dose of 2 mg/kg body weight and in subsequent
weekly imaging sessions a maintenance dose of 0.4 mg/kg
body weight [17]. Two-photon imaging was performed ona LSM 7 MP (Zeiss, Jena, Germany) equipped with stand-
ard photomultiplier detectors and a 20x water-immersion
objective (W Plan-Apochromat 20x/1.0 DIC, 1.0 NA,
Zeiss, Jena, Germany). Methoxy-X04 was excited at
750 nm by a Ti:Sa laser (MaiTai DeepSee, Spectra-Physics,
Darmstadt, Germany) and emission was collected from
440 to 500 nm. Image stacks of 850x850x250-400 μm3
were acquired using the “tilescan” mode of the microscope
control software (Zen2009/Zen2010 64bit) that performs
automatic stitching of several fields of view (2×2 were
used) with a lateral resolution of 0.83 μm and 3 μm separ-
ation distance between consecutive images. Mice were
anesthetized with isoflurane (Forene®, Abbott, Wiesbaden,
Germany) for imaging and fixed to a custom-made holder
using the glued metal plate. In subsequent imaging ses-
sions, previously imaged volumes were identified by eye
using the unique blood vessel pattern and fine adjusted by
the positions of preexisting plaques. This allowed a precise
alignment of the same imaging volume over a period of up
to 15 months. The laser intensity was adjusted to keep the
emitted fluorescence stable at different depths using the z-
correction tool in the microscope control software and
also at subsequent imaging sessions.
The following volumes were imaged: young cohort
2.888 mm3 (12 positions), old cohort 3.111 mm3 (16 posi-
tions), 12 to 18 months 1.076 mm3 (4 positions) and 12
to 27.5 months 0.559 mm3 (2 positions). The following
numbers of plaques were analyzed for each imaging co-
hort: 50 newly formed and 101 preexisting plaques (12
to 14 months), 786 plaques (18 to 20 months) and 90
plaques (12 to 27.5 months).Image processing
The images with data depth of 12 bit were analyzed as time
series of three-dimensional (3D) images in Imaris (Versions
6.2.1/7.4.2, Bitplane, Zurich, Switzerland). First, images
were contrast-normalized (i.e., based on the average and
standard deviation of intensities of 3D stacks). Plaque vol-
umes were extracted by 3D-surface-rendering with back-
ground subtraction and a threshold of 500. All detected
plaques were tracked by utilizing a custom-written Matlab
plugin for Imaris or the surface tracking module of Imaris.
Newly formed plaques were tracked back to the first time
point when they appeared and were only assessed when
present for at least 3 time points. Kinetic volume data were
exported as Excel files. 3D stacks are either displayed as
3D-volume-rendered images (“normal shading” algorithm,
Imaris) or as 3D-surface-rendered images in figures. Only
the image data of detected plaques are shown in figures to
focus the viewer’s eye on the essential information within
the images. Background signals from autofluorescence were
removed whereas contrast settings within time series were
kept constant.
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For each plaque the radii from each time point were calcu-
lated from the kinetic volume data assuming a spherical
shape of plaques [19]. Plaque densities were calculated for
each imaged position. All other calculations, curve fitting
and graphs were done in Prism (Version 5.04, GraphPad,
La Jolla, USA). Data were tested for normality using
D’Agostino-Pearson omnibus K2 test. Plaque densities and
sizes had log-normal distributions and were therefore
logarithmized which allowed for parametric statistical test-
ing. These data were displayed with an “antilog” scale to
represent the real measurement dimensions. For each
plaque a linear growth rate was determined as the slope of
a linear regression from radii calculations over time. Lin-
ear plaque growth rates were not normally distributed. All
statistical tests are specified in the figure legends.
Results
Long-term in vivo imaging over 15 months reveals
sigmoid-shaped plaque growth kinetics
Tg2576 mice express human amyloid precursor protein
with the Swedish mutation under the control of a hamster
prion protein promoter [9], leading to the accumulation of
Aβ-peptide and deposition of amyloid plaques starting at 8
to 10 months of age [9,30]. The fluorescent marker
methoxy-X04 was injected [29] to visualize fibrillar amyloid
through open-skull cranial windows over long time periods.
We imaged two different cohorts starting at 12 and
18 months of age over at least 2 months, in weekly intervals
(Figure 1a). These time-frames were chosen since plaque
development is very dynamic in the young cohort whilst
being more static in the older mice [17,22]. The mice from
the young cohort were imaged for as long as technically
feasible, limited by the clarity of the cranial window, in
order to reconcile the measurements within both age co-
horts in a single time series (Figure 1a). For precise meas-
urement of the plaque density and in order to maximize
the number of analyzable plaques, big volumes that typic-
ally sized 850 × 850× 250–400 μm3 (x, y, z dimensions)
were scanned to 27.5 months (Figure 1b; see Additional file
1 for the complete time series and the Material and
Methods section for all integrated volumes of each cohort).
All images were of optimal quality and did not suffer from
motion artifacts due to breathing or heart beating of the
animal. The volume of plaques and cerebral amyloid angio-
pathy (CAA) were assessed by 3D surface-rendering and
tracked over time. This analysis revealed a nonlinear
sigmoid-shaped curve for the mean (R2 0.983, Figure 1c)
and also integrated volume (R2 0.988, Figure 1d) of plaques.
The integrated volume of the CAA followed a sigmoid
function, too (R2 0.952, Figure 1e). In contrast, the plaque
density kinetics exhibited an asymptotic progression and
could be fitted to a one-phase association function (R2
0.975, Figure 1d).Next, we analyzed the growth kinetics for each individual
plaque separately, rather than the mean of all plaques as
previously (Figure 2). We found that single plaque kinetics
could also be fitted into a sigmoid function (Figure 2a,b). A
comparison of all fitted curves for each individual plaque
(originating from the example in Figure 1b) highlighted the
fact that only a few plaques became very large whereas the
majority of plaques showed much flatter curves with slower
Aβ accumulation (Figure 2c).
Quantification of plaque densities, sizes and growth rates
in young and aged mice
The differences in plaque densities, sizes and growth rates
between the young and old age cohorts are summarized in
Figure 3. Mean plaque density started very low in the
young cohort at 26.2 mm−3 (13.8-49.8 mm−3 CI), but in-
creased to 42.0 mm−3 (23.2-75.7 mm−3 CI) during the
2-month observation period (Figure 3a,b). This robust in-
crease in plaque density was attributed to 50 newly formed
plaques that were added to the 101 already-existing pla-
ques at the beginning of the study. In contrast, within the
old cohort only 3 new plaques were observed alongside
786 preexisting plaques. As expected, mean plaque density
was significantly higher at 18 months of age (191 mm−3;
126–292 mm−3 CI) compared to 12 and 14 months of age
(Figure 3b). Long-term imaging revealed no further signifi-
cant increase in mean plaque density, which peaked at a
plateau of 160 mm−3 (100–255 mm−3 CI) at 24 months of
age (Figure 3c, solid line).
The size of a plaque can be represented by its radius,
calculated from the measured volume assuming a spher-
ical plaque shape to facilitate comparisons [19]. At
12 months, newly-formed plaques had a mean radius of
2.27 μm (2.12-2.43 μm CI; Figure 3d), while the mean ra-
dius of preexisting plaques was 5.08 μm (4.45-5.80 μm
CI). With ageing, mean plaque radii increased further and
reached 7.98 μm at 14 months (7.31-8.72 μm CI), 10.8 μm
at 18 months (10.4-11.2 μm CI) and 16.7 μm at 27 months
(Figure 3d, 15.0-18.6 μm CI). Radii from newly formed
plaques showed the narrowest spectrum and were exclu-
sively normally distributed, while sizes from preexisting
plaques covered a wide range and had a log-normal distri-
bution (Figure 3e).
A linear regression of plaque radii over time revealed
linear growth rates reflected by the slope of the lines [19].
Nascent plaques exhibited the fastest median growth rate
at 0.475 μm/week (Figure 3f, 0.326-0.589 μm/week inter-
quartile range, IQR). Preexisting plaques from the young
cohort grew at almost the same rate (0.326 μm/week,
0.217-0.479 μm/week IQR; Figure 3f), while the old cohort
had the slowest growth rate (0.099 μm/week, −0.070-
0.262 μm/week IQR; Figure 3f). Nevertheless, an overall
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a
Figure 1 Long-term in vivo imaging of amyloid plaque growth kinetics in Tg2576 mouse model of AD. (a) A young and an old cohort
were investigated from 12 to 14 and 18 to 20 months of age, respectively, at a weekly imaging intervals. (b) Time series of 3D volume-rendered
images acquired with two-photon fluorescence microscopy showing amyloid plaques and cerebral amyloid angiopathy (CAA). The length of one
side of the squares equals 100 μm. (c) Mean volumes of all plaques over time (open circles). The black line indicates a fitted sigmoid function
(R2 0.983). Error bars show the 95% confidence intervals (CI). (d) Integrated volume of all plaques over time (open circles). The black line indicates
a fitted sigmoid function (R2 0.988). In addition, the temporal development of the plaque density is depicted (gray line) which can be fitted to an
exponential function of one phase association (R2 0.975). (e) Integrated volume of the cerebral amyloid angiopathy (open circles) with the
corresponding fit of a sigmoid function (R2 0.952).
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phases (cubic and asymptotic) of growth a bifid analysis of
the growth rates was performed to compare them to the
young and old cohorts (Figure 4a). The cubic andasymptotic growth phases are divided by the inflection
point of the fitted sigmoid function that lies at the age of
23.5 months. Therefore, plaque growth rates were deter-















































Figure 2 Illustration of a single plaque over the whole imaging period of 15.5 months. (a) Time series of a single plaque as a surface-rendered
object as derived from 3D image analysis. Scale bar represents 100 μm. (b) Volume from the plaque shown in (a) over time (open circles)
with the corresponding fit of a sigmoid function (black line). (c) Sigmoid fits of plaque volumes of all imaged plaques in one mouse. Note
the considerable variance in plaque volumes.
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growth rate was fastest in the cubic phase (median
0.365 μm/week, 0.258-0.453 μm/week IQR), whereas a
strong decline was observed for the asymptotic phase
(Figure 4c, median 0.159, 0.049-0.297 μm/week IQR).
Characteristic relationships between quantitative
plaque parameters
Relationships between plaque densities, growth rates,
size and age at plaque formation were analyzed to en-
able a detailed characterization of plaque formation and
growth. In the early stage of plaque pathology (young
cohort) plaque density at the start of imaging correlated
with plaque formation rate, the latter being an indicator
of the number of plaques formed per volume and time
unit (Figure 5a). The average plaque formation rate in
the young cohort amounted to 3.40 week−1 mm−3 (1.63-
5.16 week−1 mm−3 CI). A global comparison of all data
collected in the young and old cohort revealed an inverse
correlation between averaged plaque growth rates and
plaque densities (Figure 5b). In addition, analysis of a single
plaque over a period of 15.5 months covering the dynamic
cubic and the asymptotic phases of plaque development
provided further insight into plaque growth characteristics.
The largest plaques at the end of imaging had formed earlyduring plaque development, which leads to a strong inverse
correlation between plaque radius and age of the mouse at
plaque formation (Figure 5c). Moreover, plaque radius at
the end of imaging correlated strongly with the correspond-
ing growth rates of these plaques (Figure 5d).
There was a wide distribution of individual plaque
growth rates which lead to the question whether there
is a specific spatial relationship between growth rates of
neighboring plaques. This analysis was performed using
data from long-term imaging, the main reason being
that a longer observation period facilitates more precise
measurements of plaque growth rates. For a visual im-
pression, plaques from overview image of Figure 1b
were categorized in five classes according their growth
rates. These plaques were displayed as 3D surface-
rendered objects with their corresponding growth rate
class coded in different colors (Figure 6a). Analysis in-
volved calculating the shortest Euclidean distance of a
plaque to its nearest neighbor, which averaged 65.8 μm
(55.3-78.4 μm CI; Figure 6b). In the case of a spatial rela-
tionship, growth rates of neighboring plaques would be
expected to be similar. The analysis of two imaged posi-
tions and 46 pairs of plaques (90 plaques total), however,
revealed no such relationship (Figure 6c). Moreover, the



















































































































































Figure 3 Summary of plaque densities, radii and growth rates from all imaging cohorts. (a) Representative examples of imaged volumes
from the young and old cohort displayed as 3D volume-rendered images. The length of one side of the squares represents 50 μm. (b) Mean
plaque densities from the young (12 and 14 months) and old cohorts (18 months). (c) The kinetic of plaque density from long-term imaging
(mean from 2 positions) is shown as black line. In addition, plaque densities for each imaged position with their respective means from different
cohorts are displayed at the corresponding age. (d) The mean plaque radius and their corresponding cumulative frequency distributions (e) are
depicted for each imaging cohort including newly formed plaques from young cohort (two month imaging). For the long-term imaging cohort
plaque sizes at 27 months are shown. (f) Box plot for linear plaque growth rates and (g) their corresponding cumulative frequency distributions.
Plaque growth from 18 to 20 months of age was significant different from zero (P < 0.0001). Error bars show 95% CI (b-d), Whiskers represent
10th and 90th percentile and outliers are not shown (f). Plaque densities and radii were logarithmized before analysis (b-e). Statistical tests:
one-way ANOVA with Tukey-Kramer Post-hoc test (b, d), Kruskal-Wallis test with Dunn’s Post-hoc test (f), Wilcoxon signed-rank test (f, 18 to
20 months), paired t-test (b, 12 vs 14 months). *** P < 0.001, **** P < 0.0001
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sion from Figure 6a.
Discussion
Novel insights into plaque growth kinetics arose from sev-
eral in vivo studies in recent years. Assessment of basic
plaque growth parameters in the present study gave re-
sults consistent with the majority of findings from theliterature. The most prominent feature is the increase of
plaque size during ageing [16-20,31]. Plaques in their nas-
cent stage were smallest and constituted a distinct size
class that showed a normal distribution. Preexisting pla-
ques were much larger, depending on the age of the mice,
and displayed a log-normal distribution as also found in
humans [32]. In contrast, the rate of plaque growth de-
















































































Figure 4 Bifid analysis of the plaque growth data of long-term imaging. (a) Mean volume over time (error bars, 95% CI). A sigmoid function
was fitted to the mean volume (black line). The dotted line indicates the inflection point of the fitted curve dividing the cubic and asymptotic
parts of the function. (b) Kinetics of plaque radii. According to the cubic and asymptotic phase of volume growth two linear regressions (black
lines) were fit from 12 to 23.3 and 23.5 to 27.5 months of age. This analysis was done for each single plaque. (c) Comparison of the plaque
growth rates resulting from the bifid analysis with the values gained from the young and old imaging cohort. Black lines with error bars show
medians with interquartile range. Multiple comparisons were performed by Kruskal-Wallis test with Dunn’s Post-hoc test. ***P < 0.001
Spearman r = -0.761
P < 0.0001















age at plaque formation
[months]
c
m = 4.558 ± 1.537 (R2 = 0.494)
P = 0.016
a b m = -0.250 ± 0.058 (R2 = 0.424)
P < 0.001
d m = 49.99 ± 5.43 (R2 = 0.491)
P < 0.0001





































































Figure 5 Correlations between quantitative parameters of plaque growth dynamics. (a) Plaque formation rate as a function of plaque
density. Black line, linear regression (slope is significantly different from zero, p = 0.016). Each circle represents one imaged position. (b) Plaque
growth rate as a function of plaque density. Error bars show the 95% CI. Black line shows a linear regression of the data. The slope is statistically
significant different from zero (p < 0.001). (c) Radius of newly formed plaques at the end of long-term imaging over 15.5 months as a function of
the age of the mouse at plaque formation (N = 81 newly formed plaques from 2 positions). (d) Plaque radius at the end of long-term imaging
over 15.5 months as a function of plaque growth rate (N = 90 newly formed and preexisting plaques). Black line shows a linear regression of the
data. The slope is statistically significant different from zero. Statistical tests: F-test (a, b, d), Spearman correlation (c).




































m = 0.00043 ± 0.00039
























Figure 6 Spatial relationship between growth rates of neighboring plaques. (a) Amyloid plaques are displayed as 3D volume-rendered
images. Plaque growth rates are color-coded according to a classification into 5 bins. One square represents 100 μm. (b) Shortest distance to the
closest neighboring plaque (90 plaques), calculated from the long-term imaging over 15.5 months. The shortest distances are displayed in the
graph with the mean and 95% CI (65.8 μm, 55.3-78.4 μm CI). (c) For each pair of nearest neighbor plaques the difference between their linear
plaque growth rates and their shortest distance were calculated (open circles). No relationship between both parameters could be measured by
linear regression. The slope was not statistically significant different from zero. Statistical test: F-test (c).
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production becomes rate limiting, because an ever-
increasing total surface area of β-amyloid plaques re-
quires an increase in the amount of Aβ to maintain a
constant linear growth rate. (ii) The dissociation of Aβ
aggregates from β-amyloid plaques increases. (iii) The
number and volume of microglia around plaques in-
creases and changes plaque maintenance [33]. In
addition, the arguments (ii) and (iii) may explain nega-
tive plaque growth rates in aged animals, whereas we
can not completely exclude that at least in part data
noise is responsible for negative values. A recent study
proposed clustering of plaques as different mechanism
of plaque growth [34]. In some rare instances we also
observed fusion of plaques which we found as a conse-
quence of their volume growth in combination with
close proximity to each other (see image series Figures 1
and 3, Additional file 1). Furthermore, two studies
found no steady plaque growth [17,19,21] or plaque
growth and shrinkage [33] in the early phase of plaque
development. Possible reasons for the inconsistent find-
ings are discussed within the literature and beyond the
scope of this publication [16-20].
For the first time we were able to chart the entire kinet-
ics of growth of a single plaque, and demonstrate a sig-
moidal growth curve comprising both a cubic and an
asymptotic phase (Figures 1 and 2, Additional file 2: Figure
S1a-b). Recent studies in humans using positron emission
tomography (PET) applying an amyloid tracer (Pittsburgh
compound B, PiB) [10,35,36] also found a plateau and/or a
sigmoid-shaped progression of β-amyloid accumulation
[7,13].Long-term imaging over at least 6 months revealed
an asymptotic increase in plaque densities that could
be fitted to a one-phase association function. This find-
ing is congruent with a previously described decline in
the rate of plaque formation with ageing [16-20,31].
Interestingly, plaque growth and plaque density are
inter-related, as shown by correlation analysis of both
parameters.
During the dynamic phase of plaque development
(young cohort) a distinct correlation between plaque dens-
ity and plaque formation rate was observed. In humans, a
similar relationship was found using PiB-PET which re-
vealed a higher increase in PiB retention in the second
PET scan after 18 months if those subjects had a positive
PiB signal in the first PET scan [37]. Fibrillization of Aβ
has been convincingly shown by in vitro studies to consist
of a two-step process that requires first the nucleation of a
seed, before polymerization into amyloid fibrils [14,38].
Furthermore, a direct relationship was measured in vitro
between Aβ concentration and the ability to form nucle-
ation seeds [8,39]. For a mouse model of AD, a similar
correlation between Aβ concentration in the interstitial/
cerebrospinal fluid and plaque load (a relative measure
of the area of a brain slice that is covered by plaques)
was reported [40,41]. Taking together the knowledge
from these studies with our results, a link between
plaque density and Aβ production can be established
since there is a strong correlation between plaque dens-
ity and plaque load (Additional file 2: Figure S1c). Inter-
estingly, plaque densities varied over a wide range
which suggests that Aβ production varies between indi-










CAβ > Ccritical CAβ  Ccritical CAβ < Ccritical
Figure 7 Model for the relationship between plaque density
kinetics and amyloid plaque growth in vivo. The term ccritical refers
to the minimum critical concentration of Aβ that is necessary to form
plaque seeds (a prerequisite discovered by in vitro studies). This initial
step of plaque formation was observed by recording the plaque
density kinetics in vivo. According to the plaque density kinetics and
applying the aforementioned requirement different relations of the Aβ
concentrations comparative to the critical minimum concentration can
be assigned to the different growth phases.
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ground of Tg2576 mice which may be lead to differences
in epigenetic regulation and/or promotor activities [9].
Nevertheless, all 4 animals of the young cohort covered
the complete range of plaque densities measured in 30
animals of a further study (Additional file 2: Figure
S1d). In addition, the predictive value of plaque density
regarding Aβ production could be limited in mouse
models without a constant Aβ production over time
[23]. Another limitation worth noting is that methoxy-
X04 in mice, and also PiB in humans, detect insoluble
fibrillar but not soluble Aβ species [29,36,43,44]. Fur-
thermore, in vivo two-photon imaging using methoxy-
X04 allows for the resolution of single amyloid plaques
in brain regions accessible by this technique while PET
imaging allows to image the whole brain, but with a
resolution limit of about 1 mm3.
The observation of a steady linear increase in plaque
radius over several months during the cubic growth
phase presumes that Aβ concentration is not rate limit-
ing. Otherwise a decline in growth would be expected
due to the ever-increasing surface area of β-amyloid pla-
ques which requires a proportional increase in the
amount of Aβ to maintain a constant linear growth rate.
A comparison of plaque growth of the Tg2576 with
the APPPS1 mouse model that was investigated by two
other studies, using exactly the same methods and
data analysis, supports this hypothetical assumption
[16-20,31]. Although APPPS1 mice produce much more
Aβ and accumulation starts much earlier than in Tg2576
mice [9,19,23,30] median plaque growth rates were about
0.3 μm/week in both mouse models [16-20,31]. In
conclusion, there appears to be an upper limit for me-
dian plaque growth in vivo that was also identified in vitro
for the growth of Aβ fibrils [45]. The higher Aβ produc-
tion in APPPS1 mice causes a much higher plaque density
compared to Tg2576 mice (631 mm−3, 521–762 mm−3 CI
vs. 26.2 mm−3, 13.8-49.8 mm−3 CI, Additional file 2:
Figure S1e, Figure 3b). Accordingly, a 10-fold higher rate
of plaque formation was reported for APPPS1 mice [19]
compared to Tg2576 mice (35 vs. 3.40 week−1 mm−3).
Although median plaque growth rates were similar in
both mouse models, individual plaque growth rates
showed a big variance. In addition, plaque growth rates
of neighboring plaques did not correlate. Combining
both results, it is most likely that different conditions
within the microenvironment of plaques are causal
for the different growth rates. Such conditions could
include pH, ionic strength and hydrophobicity of the
Aβ peptide, as well as interactions with membranes
[46-49]. Even though the analysis of a single animal
is statistically not sufficient, the unique dataset con-
taining a complete plaque growth kinetic further sup-
ports this idea. It highlights that large plaques wereformed early during Aβ accumulation and have the
highest growth rates. This in turn suggests that pla-
ques are first formed at sites where the best conditions
exist.
In conclusion, the comprehensive plaque density and
growth kinetics point to a three-stage model of β-amyloid
accumulation (Figure 7). According to the kinetics of
plaque volume three phases can be distinguished: (1) a
cubic (2) a transition and (3) a saturation phase. Initially, a
high concentration of Aβ above the critical concentration
leads to the formation of many new plaques (cubic
phase). Later, the large number of plaques may serve as
“dumps” for free Aβ, so that its concentration gradually
drops, causing the formation of fewer plaques during
the transition phase, while existing plaques continue
growing. In the saturation phase, single plaques show
an overall slower growth due to the large number of
plaques, while no new plaques are deposited, thus Aβ
production becomes rate-limiting. Furthermore, due to
the same sigmoid-shaped characteristic of plaque accu-
mulation in humans, albeit over one to two decades,
such a model may help extrapolate observations from
AD mouse models to the situation in humans, parti-
cularly with regards to pre-clinical testing of Aβ-lowering
therapeutics [7,13]. In particular, the determination of
plaque density kinetics may be more sensitive than
analyzing plaque volume kinetics when evaluating
anti-aggregation agents, since Aβ concentration is not
rate-limiting to plaque growth in the early stage of
amyloid deposition.
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Additional file 1: This video shows the complete plaque growth
kinetic from 12 to 27.5 months of age (image data from Figure 1b).
Data is displayed as 3D-volume rendered images. Big squares represent
100 μm.
Additional file 2: Figure S1. (a) Plaque volume data of two additional
mice over 6 months. Mean plaque volumes were best fit with either a
sigmoid function (mouse1: open triangles) or a cubic function (mouse2:
open circles). Error bars show 95% CI. (b) Kinetics of the plaque densities
(dotted lines) and mean volumes (colored lines showing nonlinear fitted
functions) over time for all 3 mice imaged at least over a period of
6 months. Vertical dotted lines indicate time points when plaque
densities did not further increase. (c) Relationship of amyloid plaque load
(integrated plaque volume/imaging volume) and plaque density for each
imaged position. Linear regression was performed for each age cohort.
The slopes were statistically significant different from zero (F-test). (d)
Comparison of the plaque densities between the young cohort of the
current study and another group of mice of a further study. Line and
error bars display mean with 95% CI. The means were not significant
different (t-test). (e) Plaque density measured in APPPS1 mice at
4 months of age. Line and error bars display mean with 95% CI. The
equations were used for curve fitting.
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